Eposin Injection (Etoposide): Targeted Topoisomerase II Inhibitor for Advanced Oncology – Global Supply by Ernest Oncology
In the evolving clinical landscape of 2026, Eposin Injection (containing the active ingredient Etoposide) remains an indispensable antineoplastic agent. As a semi-synthetic derivative of podophyllotoxin, Eposin is a cornerstone in multi-agent chemotherapy regimens designed to treat various solid tumors and hematological malignancies with high precision.
Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a leading Exporter, Bulk Supplier, and Distributor from India. We facilitate the GMP-compliant international distribution of Eposin to London (UK), the United States, Abu Dhabi (UAE), Australia, and South Africa, ensuring rigorous quality standards and validated cold-chain logistics.
Technical Product Information: Eposin Injection
Eposin is a cell-cycle-specific cytotoxic agent that acts primarily in the G2 and S phases of cellular division. It is supplied as a sterile, non-aqueous solution for intravenous administration after proper dilution.
Product Specifications
Active Ingredient: Etoposide USP/BP/IP
Common Strengths: 100 mg / 5 mL Vials
Pharmacological Class: Antineoplastic (Podophyllotoxin derivative)
Storage Requirements: Store at controlled room temperature (15°C to 25°C). Do not freeze. Protect from light.
Primary Clinical Indications
Small Cell Lung Cancer (SCLC): Typically utilized as a first-line therapy in combination with other chemotherapeutic agents like Cisplatin.
Refractory Testicular Tumors: For patients who have already received appropriate surgical and chemotherapeutic treatment.
Acute Monocytic and Myelomonocytic Leukemia: Integrated into induction and consolidation protocols.
Hodgkin’s & Non-Hodgkin’s Lymphoma: A key component in salvage and high-dose therapy regimens.
Choriocarcinoma: Part of multi-drug protocols for gestational trophoblastic tumors.
Mechanism of Action: How Eposin Works
Eposin exerts its therapeutic effect by inhibiting the enzyme DNA Topoisomerase II, which is essential for DNA replication and transcription.
Complex Stabilization: Eposin binds to the DNA-Topoisomerase II complex, preventing the re-ligation of DNA strands.
Double-Strand Breaks: This leads to an accumulation of permanent double-strand breaks in the cancer cell's DNA.
Mitotic Arrest: The genomic damage triggers the cell's internal checkpoints, arresting the cell cycle in the G2 phase.
Apoptosis: The irreparable damage ultimately results in programmed cell death (apoptosis) of the malignant cells.
Global Supply Chain: UK, USA, UAE, Australia, & South Africa
Ernest Oncology specializes in the logistical complexities of exporting high-quality oncology injectables from India to key international healthcare markets.
United Kingdom & London: We serve NHS Trusts and private oncology clinics in London, adhering to all MHRA import standards and safety protocols.
United States: Bulk supply for hospital systems and specialty pharmacies seeking verified Indian pharmaceutical exports at competitive rates.
Abu Dhabi & UAE: Supporting the UAE’s advanced medical infrastructure with fast-track, secure shipping to major oncology hubs.
Australia: Strategic distribution to regional hospitals and wholesalers, maintaining strict compliance with TGA frameworks.
South Africa: Strengthening the African healthcare sector with affordable, high-quality cancer drugs from GMP facilities.
📞 Contact Ernest Oncology — Pharmaceutical Exporter from India
(Group of Ernest Pharmaceutical Pvt. Ltd.)
Partner with a verified leader for the bulk procurement of oncology injectables and specialized cancer care products.
🌐 Websites:
📧 Email:
📦 Business Type: Exporter | Bulk Supplier | Distributor
📲 WhatsApp: +91 93599 02383
🔗 Instant Chat:
